Roche said on May 7, 2026 that it had signed a definitive merger agreement to acquire PathAI, a Boston company that builds artificial intelligence tools and software for pathology labs and drug developers. Roche agreed to pay $750 million upfront and up to $300 million more in milestone payments, putting the total value at up to $1.05 billion.
The deal was expected to close in the second half of 2026, subject to antitrust and regulatory approvals and other customary conditions. After closing, PathAI will become part of Roche's Diagnostics division.
The two companies were not strangers. They began working together in 2021 and widened the partnership in 2024 to develop AI-enabled companion diagnostic algorithms, which help identify which patients are likely to benefit from a particular drug.
What PathAI built
PathAI was co-founded by Andy Beck, its chief executive, and Aditya Khosla, and its platform launched in 2016. The company trains AI models to analyse images of patient tissue, the slides that pathologists examine to diagnose cancer and other diseases.
Its main product for hospitals and labs is AISight, an image management system that lets a digital pathology lab view, organise and analyse scanned slides, with analysis and workflow tools in the same interface. PathAI's website lists a version called AISight Dx as cleared by the US Food and Drug Administration through the 510(k) process and as carrying CE-IVDR marking in Europe.
PathAI also sells AI services to pharmaceutical companies for clinical trials and translational research. Labcorp expanded its collaboration with PathAI earlier in 2026 to use the platform in its anatomic pathology labs and at hospital sites, according to MedTech Dive.
“Digital pathology has the potential to improve precision diagnosis of cancer”
Why Roche is buying
Roche said the acquisition would strengthen its position in digital pathology as labs move from manual workflows to automated, AI-driven processes. It plans to scale AISight globally as part of its digital pathology portfolio and to combine PathAI's tools with its own oncology diagnosis platforms.
Matt Sause, chief executive of Roche Diagnostics, said digital pathology has the potential to improve precision diagnosis of cancer, and that combining the two companies' tools could give physicians better information and potentially improve outcomes for patients.
On the pharmaceutical side, Roche said PathAI's AI capabilities would complement its companion diagnostics business. Together the companies aim to support biomarker discovery, the identification of drug targets and the creation of new diagnostic tools.
Andy Beck said joining Roche marked a new era for PathAI and that Roche's global infrastructure and expertise would bring its digital diagnostics technology to patients around the world.
The founders and the funding
PathAI raised a $60 million Series B in 2019, led by General Atlantic with participation from General Catalyst and other existing investors. In May 2021 it closed a $165 million Series C co-led by D1 Capital Partners and Kaiser Permanente. General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners and Refactor Capital also took part, along with strategic investors Bristol-Myers Squibb, Labcorp and Merck's Global Health Innovation Fund.
At the time of the Series C, Built In Boston reported that PathAI had 165 employees, about 130 of them in Boston, up from 60 in 2019. Roche did not give a current headcount or say what return PathAI's investors would receive.
A consolidating market
Other diagnostics companies have also been buying in the field. In 2025 Tempus AI bought Paige, another digital pathology company, for just over $81 million, according to MedTech Dive. Roche's price for PathAI, before milestones, is more than nine times that figure.
Roche, founded in 1896 in Basel, sells products in more than 150 countries through its Pharmaceuticals and Diagnostics divisions. Until now its relationship with PathAI was a partnership focused on companion diagnostic algorithms; once the deal closes, both the AISight lab software and that algorithm work will sit inside Roche Diagnostics.
